Pfizer and BioNTech SE announced today that the U.S. Food and Drug Administration (FDA) granted emergency use authorization (EUA) to provide a single booster dose of the companies’ Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine in children 6 months through 4 years of age (also referred to as under 5 years of age) at least 2 months after completion of primary vaccination with three doses of the Pfizer-BioNTech COVID-19 Original Vaccine. The bivalent vaccine is also authorized in this age group as the third dose of a three dose-primary series; for these children, a booster (fourth) dose is not authorized at this time.
The EUA is based on data from substudies within the companies’ Phase 1/2/3 study (NCT05543616) evaluating the safety, tolerability and immunogenicity of a fourth dose of the bivalent vaccine in children 6 months through 4 years of age (n=300). Safety and immunogenicity were assessed in a subset of study participants 6 months through 4 years of age (n=60), demonstrating that a booster (fourth) dose of the Omicron BA.4/BA.5-adapted bivalent vaccine elicited improved Omicron BA.4/BA.5-neutralizing antibody responses compared to participants who received three doses of the companies’ original vaccine. The safety and tolerability profile of the bivalent vaccine was similar to that of the original vaccine.
Based on the latest real-world evidence, Omicron BA.4/BA.5-adapted bivalent vaccines appear to be protective against symptomatic COVID-19 disease in adults caused by both BA.4/BA.5 and XBB Omicron sublineages, the latter of which currently account for more than 85% of COVID-19 cases in the U.S. Additional real-world evidence collected between September 2022 and December 2022 shows that among older adults, receiving an mRNA-based bivalent booster provided greater vaccine effectiveness against COVID-19 hospitalization compared to receiving two or more doses of the companies’ original wild-type vaccine administered two months earlier. This was observed during a time when different Omicron sublineages were circulating, including XBB.1.5 which started to circulate in the second half of December.
Pfizer and BioNTech have also submitted an application to the European Medicines Agency (EMA) to extend the Omicron BA.4/BA.5-adapted bivalent vaccine’s marketing authorization to include use in children 6 months through 4 years of age as both primary series (all three doses) and booster vaccination (fourth dose). Currently, the bivalent vaccine is authorized in the European Union (EU) as a booster dose for ages 5 years and older. The companies plan to submit applications to other regulatory authorities worldwide for the use of their Omicron BA.4/BA.5-adapted bivalent vaccine among children under 5 years of age.
The Pfizer-BioNTech COVID-19 Vaccines (COMIRNATY®) are based on BioNTech’s proprietary mRNA technology and were developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorization Holder for BNT162b2 (Original) and BNT162b2 Bivalent (Original/Omicron BA.4/BA.5) in the United States, the European Union, the United Kingdom, Canada and other countries, and the holder of emergency use authorizations or equivalents in the United States (jointly with Pfizer) and other countries.
Scheduling Procedures
To schedule a vaccine appointment at Walgreens, you will need to provide some basic information, including your name, date of birth, and contact information. You will also need to indicate your eligibility based on the criteria established by your state or local health department.
If you are eligible, you will be able to select a location and an appointment time that works for you. Some Walgreens locations may offer walk-in appointments, but it’s always best to schedule an appointment in advance to ensure that you will be able to receive the vaccine at your desired time.
When you arrive at the Walgreens location for your appointment, you will need to bring your ID and your insurance card, if you have one. You will also need to wear a mask and practice social distancing to help prevent the spread of COVID-19.
After you receive the vaccine, you will need to wait for a short period of time to ensure that you do not experience any adverse reactions. Walgreens staff will monitor you during this time and provide you with any necessary information about the vaccine and what to do if you experience any side effects.
Overall, scheduling a COVID-19 vaccine appointment at Walgreens is a relatively simple process that can help protect you, your loved ones, and your community from the virus. By following the guidelines established by your local health department and working with Walgreens staff, you can receive the vaccine safely and with minimal disruption to your daily routine.
Vaccinations are available at Walgreens. Visit Walgreens.com/ScheduleVaccine, use the Walgreens app or call 1-800-WALGREENS.
